Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:42:07.376Z.
Consensus retrieved: 2026-10-06T13:12:29.969Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:42:07.376Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b
Forward PE Ratio (N/A) = Dated Quote Price ($2.66) / Consensus Forward EPS ($-2.01)
FORWARD PE RATIO
N/A
Kalaris Therapeutics Inc
Market Cap
$58.06M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $58.06M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.66, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.01 | $-2.10 – $-1.87 | 6 | n/m |
| 2027-12-31 | $-1.66 | $-1.83 – $-1.45 | 6 | n/m |
| 2028-12-31 | $-2.42 | $-3.85 – $-1.26 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
